Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5822581 | 0.76 | HSD11B1 (0.41) | ALDH1A1HPGDCYP19A1 | |
| SCHEMBL9444404 | 0.71 | BRD4 (0.47) | ALDH1A1MAPTTDP1BRD4 | |
| SCHEMBL11368289 | 0.70 | CYP17A1 (0.62) | CYP17A1OPRK1MEN1NR1I2USP2 | |
| SCHEMBL27217012 | 0.69 | ESR1 (0.42) | ALDH1A1MAPTKMT2ATDP1BRD4 | |
| SCHEMBL11330557 | 0.69 | CYP19A1 (0.40) | CYP17A1OPRK1MEN1NR1I2USP2 | |
| SCHEMBL11335494 | 0.69 | CYP19A1 (0.40) | OPRK1ALDH1A1KMT2ATDP1CYP19A1 | |
| Bifonazole SCHEMBL394764 | 0.69 | CYP17A1 (1.00) | CYP17A1OPRK1MEN1NR1I2USP2 | |
| Bifonazole SCHEMBL1606037 | 0.69 | CYP17A1 (1.00) | CYP17A1OPRK1MEN1NR1I2USP2 | |
| SCHEMBL8865912 | 0.69 | CYP19A1 (0.40) | CYP17A1OPRK1MEN1NR1I2USP2 | |
| Bifonazole SCHEMBL1551534 | 0.69 | CYP17A1 (1.00) | CYP17A1OPRK1MEN1NR1I2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082126-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | NOVELMED THERAPEUTICS, INC. | 2011-04-07 | — | — | US | claimed |
| US-20150216876-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | NOVELMED THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-9040507-B2 | Method for treating inflammatory conditions | NOVELMED THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20110082126-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | NOVELMED THERAPEUTICS, INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2009149081-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | NOVELMED THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216876-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | ESR2, ESRRA, GPER1 | CYP17A1 12/4885OPRK1 690/4885MEN1 2416/4885 |
| US-20110082126-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | ESR2, ESRRA, GPER1 | CYP17A1 12/4885OPRK1 690/4885MEN1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.